ImmunityBio (IBRX) Gains 17% in the Past Week: Here's Why

Anktiva, in combination with Bacillus Calmette-Guérin (BCG), got FDA approval in April 2024 for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors. Year to date, shares of IBRX have rallied 44.8% against the industry's 4.1% decline. Patients were treated for up to 37 months, with their tumor status regularly assessed through cystoscopy and urine cytology. The monitoring will continue for up to five years f ...